Exact Therapeutics AS, Oslo, Norway, a clinical stage precision medicine company, announces a collaboration with GE Healthcare to develop an ultrasound probe to be used in forthcoming studies using Acoustic Cluster Therapy (ACT) across multiple disease conditions.
“We are delighted to collaborate with GE Healthcare, a leader in the field of diagnostic imaging and ultrasound,” says Rafiq Hasan, MBBS, CEO of Exact Therapeutics AS. “We look forward to working closely with GE Healthcare in developing an innovative ultrasound probe with the goal of enabling effective deployment of the ACT therapeutic amplification platform across indications for our forthcoming phase II clinical development program.”
ACT is a proprietary formulation consisting of microbubbles and microdroplets that are activated through the application of ultrasound with the consequent increase in targeted delivery of a co-administered therapeutic agent. ACT is supported by a strong and broad preclinical package demonstrating therapeutic enhancement in multiple oncology models (pancreatic, breast, colon, prostate) as well as controlled blood-brain barrier opening. Currently ACT is being evaluated in the international ACTIVATE Phase I clinical trial in patients with metastatic colorectal and pancreatic cancer at the Royal Marsden Hospital in London.